Therapy News and Research

RSS

Teva Pharmaceutical Industries net sales up 25%

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2009.

3 Nov 2009

Quintiles to deliver AstraZeneca’s clinical pharmacology studies

Quintiles today announced that it has entered into in an industry-leading clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas and around the globe.

3 Nov 2009

Therapy with EBV-specific CTLs effective for severely immune-compromised patients

Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital.

3 Nov 2009

IMC-RT does not benefit breast cancer patients

After mastectomy, breast cancer patients who receive radiation treatment to the lymph nodes located behind the breast bone do not live longer than those who do not receive radiation to this hard-to-treat area, according to a randomized 10-year study presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

ASTRO commends CMS for limiting payment reductions proposed for radiation oncology

ASTRO, the American Society for Radiation Oncology, today praised the Centers for Medicare and Medicaid Services (CMS) for limiting the payment reductions initially proposed for radiation oncology and spreading the remaining cuts over four years.

3 Nov 2009

AST develops two new holiday season tip sheets for families of children with autism

Autism Spectrum Therapies (AST), an agency providing behavior therapy and other autism services throughout Southern California, has developed two new holiday season tip sheets especially for families of children with autism: Stress-Free Holidays and Top Toy Recommendations.

3 Nov 2009

Extra dose of proton radiation therapy reduces prostate cancer recurrences

Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009

New imaging technique for treatment of breast cancer

Researchers at Rush University Medical Center and Argonne National Laboratory are collaborating on a study to determine if an imaging technique used by NASA to inspect the space shuttle can be used to predict tissue damage often experienced by breast cancer patients undergoing radiation therapy. The study is examining the utility of three-dimensional thermal tomography in radiation oncology.

3 Nov 2009

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

Cardium Therapeutics today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate.

3 Nov 2009

NIA funds national Testosterone Trial, Penn Medicine to lead

Penn Medicine will lead a new national $45 million clinical trial to test whether testosterone therapy can favorably affect certain conditions affecting older men. Low serum testosterone may contribute to a number of problems affecting older men, including decreased ability to walk, loss of muscle mass and strength, decreased vitality, decreased sexual function, impaired cognition, cardiovascular disease and anemia. While testosterone normally decreases with age, in some men, low levels of testosterone may contribute to these debilitating conditions.

2 Nov 2009

BioVex publishes OncoVEX (GM-CSF) Phase 2 study results

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.

2 Nov 2009

Also in Global Health News: Undernutrition in Afghanistan; Namibia's HIV clinics, outreach programs

A Lancet World Report examines the deadly toll undernutrition is having on the people of Afghanistan, where the "issues of poverty and undernutrition have received curiously little attention: about a third of the population, more than 7 million people, are food insecure, according the U.N. World Food Programme (WFP).

2 Nov 2009

NIH-funded study using SphygmoCor published

AtCor Medical the developer and marketer of the SphygmoCor® system which measures central blood pressure and arterial stiffness noninvasively, today announced the publication of a key National Institutes of Health (NIH)-funded study(1) using SphygmoCor in the Journal of the American College of Cardiology (JACC).

2 Nov 2009

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has commenced a randomized, double-blind, placebo-controlled Pilot Study of up to 165 persons who have type 2 diabetes, the most common form of diabetes.

2 Nov 2009

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

Dendreon Corporation today announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T), the Company's lead investigational product, to the U.S. Food and Drug Administration (FDA). Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

2 Nov 2009

A look at faculty health

On average, research shows, the United States loses the equivalent of at least one entire medical school class each year to suicide1 - as many as 400 physicians. The book Faculty Health in Academic Medicine: Scientists, Physicians, and the Pressures of Success (Humana Press/Springer), by faculty at The University of Texas M. D. Anderson Cancer Center and other national medical experts, breaks new ground in a first-of-its-kind look at faculty health.

2 Nov 2009

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Gilead Sciences, Inc., in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).

2 Nov 2009

FDA issues a Complete Response Letter for GTx' toremifene NDA

GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).

2 Nov 2009

ZirMed forges alliance with Raintree Systems to jointly market their combined solutions

ZirMed®, a national provider of revenue cycle management services for healthcare practices, and leading integrated healthcare technology company Raintree Systems Inc. today announced a working partnership to jointly market their combined solutions to current and prospective customers. As a result of the partnership, ZirMed's flagship revenue cycle management platform will be integrated with Raintree's practice management and Electronic Medical Records (EMR) products, giving users state-of-the-art technology with which to better manage their daily operations.

2 Nov 2009

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.

2 Nov 2009

Therapy News and Research

Teva Pharmaceutical Industries net sales up 25%

Quintiles to deliver AstraZeneca’s clinical pharmacology studies

Therapy with EBV-specific CTLs effective for severely immune-compromised patients

IMC-RT does not benefit breast cancer patients

ASTRO commends CMS for limiting payment reductions proposed for radiation oncology

AST develops two new holiday season tip sheets for families of children with autism

Extra dose of proton radiation therapy reduces prostate cancer recurrences

New imaging technique for treatment of breast cancer

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

NIA funds national Testosterone Trial, Penn Medicine to lead

BioVex publishes OncoVEX (GM-CSF) Phase 2 study results

Also in Global Health News: Undernutrition in Afghanistan; Namibia's HIV clinics, outreach programs

NIH-funded study using SphygmoCor published

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

A look at faculty health

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

FDA issues a Complete Response Letter for GTx' toremifene NDA

ZirMed forges alliance with Raintree Systems to jointly market their combined solutions

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News